CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes

Alexander Roberts; Gillian Grafton; Andrew D. Powell; Kristian Brock; Chunlin Chen; Dejian Xie; Jinkun Huang; Shuang Liu; Alison J. Cooper; Catherine A. Brady; Omar Qureshi; Zania Stamataki; David D. Manning; Nicholas A. Moore; Bruce J. Sargent; Peter R. Guzzo; Nicholas M. Barnes

doi:10.1124/jpet.119.261008

CSTI-300 (SMP-100); a novel 5-HT₃ receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes

Alexander Roberts, Gillian Grafton, Andrew D. Powell, Kristian Brock, Chunlin Chen, Dejian Xie, Jinkun Huang, Shuang Liu, Alison J. Cooper, Catherine A. Brady, Omar Qureshi, Zania Stamataki, David D. Manning, Nicholas A. Moore, Bruce J. Sargent, Peter R. Guzzo, Nicholas M. Barnes^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (SciVal)

Original language	English
Pages (from-to)	122-134
Number of pages	13
Journal	Journal of Pharmacology and Experimental Therapeutics
Volume	373
Issue number	1
DOIs	https://doi.org/10.1124/jpet.119.261008
Publication status	Published (VoR) - 1 Apr 2020

Funding

Funded as a research and development program by Albany Molecular Research, Inc., Chengdu SciMount Pharmatech Co. Ltd, and ConSynance Therapeutics, Inc.

Access to Document

10.1124/jpet.119.261008

Cite this

Roberts, A., Grafton, G., Powell, A. D., Brock, K., Chen, C., Xie, D., Huang, J., Liu, S., Cooper, A. J., Brady, C. A., Qureshi, O., Stamataki, Z., Manning, D. D., Moore, N. A., Sargent, B. J., Guzzo, P. R., & Barnes, N. M. (2020). CSTI-300 (SMP-100); a novel 5-HT₃ receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes. Journal of Pharmacology and Experimental Therapeutics, 373(1), 122-134. https://doi.org/10.1124/jpet.119.261008

@article{e6ec9b06f94842e39db21fd3d56788fd,

title = "CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes",

author = "Alexander Roberts and Gillian Grafton and Powell, \{Andrew D.\} and Kristian Brock and Chunlin Chen and Dejian Xie and Jinkun Huang and Shuang Liu and Cooper, \{Alison J.\} and Brady, \{Catherine A.\} and Omar Qureshi and Zania Stamataki and Manning, \{David D.\} and Moore, \{Nicholas A.\} and Sargent, \{Bruce J.\} and Guzzo, \{Peter R.\} and Barnes, \{Nicholas M.\}",

note = "Funding Information: Funded as a research and development program by Albany Molecular Research, Inc., Chengdu SciMount Pharmatech Co. Ltd, and ConSynance Therapeutics, Inc. Publisher Copyright: Copyright {\textcopyright} 2020 by The American Society for Pharmacology and Experimental Therapeutics.",

year = "2020",

month = apr,

day = "1",

doi = "10.1124/jpet.119.261008",

language = "English",

volume = "373",

pages = "122--134",

journal = "Journal of Pharmacology and Experimental Therapeutics",

issn = "0022-3565",

publisher = "American Society for Pharmacology and Experimental Therapeutics",

number = "1",

}

Roberts, A, Grafton, G, Powell, AD, Brock, K, Chen, C, Xie, D, Huang, J, Liu, S, Cooper, AJ, Brady, CA, Qureshi, O, Stamataki, Z, Manning, DD, Moore, NA, Sargent, BJ, Guzzo, PR & Barnes, NM 2020, 'CSTI-300 (SMP-100); a novel 5-HT₃ receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes', Journal of Pharmacology and Experimental Therapeutics, vol. 373, no. 1, pp. 122-134. https://doi.org/10.1124/jpet.119.261008

CSTI-300 (SMP-100); a novel 5-HT₃ receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes. / Roberts, Alexander; Grafton, Gillian; Powell, Andrew D. et al.
In: Journal of Pharmacology and Experimental Therapeutics, Vol. 373, No. 1, 01.04.2020, p. 122-134.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes

AU - Roberts, Alexander

AU - Grafton, Gillian

AU - Powell, Andrew D.

AU - Brock, Kristian

AU - Chen, Chunlin

AU - Xie, Dejian

AU - Huang, Jinkun

AU - Liu, Shuang

AU - Cooper, Alison J.

AU - Brady, Catherine A.

AU - Qureshi, Omar

AU - Stamataki, Zania

AU - Manning, David D.

AU - Moore, Nicholas A.

AU - Sargent, Bruce J.

AU - Guzzo, Peter R.

AU - Barnes, Nicholas M.

N1 - Funding Information: Funded as a research and development program by Albany Molecular Research, Inc., Chengdu SciMount Pharmatech Co. Ltd, and ConSynance Therapeutics, Inc. Publisher Copyright: Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

PY - 2020/4/1

Y1 - 2020/4/1

UR - https://www.scopus.com/pages/publications/85082093389

UR - https://www.scopus.com/inward/citedby.url?scp=85082093389&partnerID=8YFLogxK

U2 - 10.1124/jpet.119.261008

DO - 10.1124/jpet.119.261008

M3 - Article

C2 - 32102919

AN - SCOPUS:85082093389

SN - 0022-3565

VL - 373

SP - 122

EP - 134

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

IS - 1

ER -

CSTI-300 (SMP-100); a novel 5-HT₃ receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndromes

Funding

Access to Document

Other files and links

Fingerprint

Cite this